GI-213 / GI Innovation - LARVOL DELTA

GI Innovation decides to increase capital by allocating 80 billion won to shareholders [Google translation] (Hankyung) - "GI Innovation is conducting a paid-in capital increase with shareholder allocation of 80 billion won...The new share allocation base date is February 12, 2025, the listing date is April 10, 2025, and Korea Investment & Securities will be the lead manager for the paid-in capital increase....The company plans to use the raised funds for Korean/US phase 1/2 clinical trials of immunotherapy drugs GI-101A and GI-102, clinical trials of metabolism-modulating anticancer drug GI-108, R&D of new pipelines such as GI-305, GI-213, and GI-128 other operating funds, etc."

Financing • Solid Tumor